^
    Back
    Association details:
    Biomarker:WT1 expression
    Cancer:Malignant Pleural Mesothelioma
    Drug:Opdivo (nivolumab) (PD1 inhibitor) +
    Zeltherva (galinpepimut-S) (Wilms tumor 1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    SELLAS Life Sciences Press Release
    Title:

    SELLAS Reports Encouraging Updated Clinical Data from Ongoing Mesothelioma Study of Galinpepimut-S (GPS) Combined with Opdivo

    Published date:
    06/24/2021
    Excerpt:
    All patients had the MPM epithelioid and/or sarcomatoid variant, a tumor which is universally expressing Wilms Tumor 1 (WT1)...Average overall survival (OS) was 35.3 + 24.0 weeks with a median OS of 35.4 weeks, while average progression-free survival (PFS) was 8.8 + 4.2 weeks with a median PFS of seven weeks, both at a median follow-up of 35.4 weeks.
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    SELLAS Life Sciences Press Release
    Title:

    SELLAS Announces Promising Initial Clinical Data for Galinpepimut-S (GPS) in Combination with Checkpoint Inhibitors in Two Solid Tumor Indications

    Published date:
    12/21/2020
    Excerpt:
    SELLAS Life Sciences Group, Inc...today announced initial data from two clinical studies of galinpepimut-S (GPS), the Company’s Wilms Tumor-1 (WT1)-targeting peptide immunotherapeutic, in combination with checkpoint inhibitor therapies in patients...Mesothelioma Study of GPS in Combination with Opdivo® Shows Clinically Intriguing Activity with Median Progression Free Survival of at Least 10 Weeks...